



# Corporate fact sheet

## WHO WE ARE

A clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®.

- Know-how licence from the University of Warwick – spun-out of polymer chemistry group
- Exclusive, worldwide licence for revolutionary patented adhesive from Bostik
- Novel adhesive allows formulation of a wide range of drugs as transdermal patches



TEPI Patch

## COMPANY HISTORY

### 2015

- Company founded with Seed funding from Mercia Technologies & IP from Uni of Warwick
- Exclusively licenced novel adhesive from Bostik

### 2017

- Selection of contract manufacturer for GMP production
- Chairman, COO and Head of Clinical appointed
- Approximately £4m raised, led by Mercia Technologies

### 2018

- Pilot scale manufacturing equipment installed
- GMP manufacture of Ibuprofen TEPI Patch® by contractor
- Completed 2 clinical trials – novel adhesive not irritant

## BUSINESS MODEL

### Develop own products & license for specific territories

- Best-in-class products to address global markets
- Focus on products for pain and CNS diseases
- Product generation engine to feed the pipeline
  - » Licence products for commercialisation

### Develop products for partners & license technology


- Rapid two-stage feasibility studies
  - » Multiple formulations developed and tested against target profile
  - » Formulation optimisation and manufacturing process development
  - » Licence technology for partner to develop their TEPI Patch® product

To find out more please contact the Medherant team

Phone: +44 (0)24 7632 3060 | Email: [info@medherant.co.uk](mailto:info@medherant.co.uk) | [www.medherant.co.uk](http://www.medherant.co.uk)

## BENEFITS OF TRANSDERMAL PATCHES

- Better dose control vs creams, gels & ointments
- Avoidance of GI damage & 1st pass metabolism
- Steady release of drug – avoids plasma spikes
- Less frequent drug administration
- Improved patient compliance



## LIMITATIONS OF CURRENT TECHNOLOGIES

- Unsuitable for many drugs as unable to load sufficient drug into the patch
- Loss of adhesion so the full dose is not delivered, reducing efficacy
- Unattractive & uncomfortable with black ring around the edge of the patch ('cold flow')



## STRATEGIC VISION

To build a sustainable transdermal drug delivery company that generates value for patients, partners and investors by leveraging our unique TEPI Patch® technology to develop innovative products to treat pain and CNS diseases.

## TEPI PATCH® TECHNOLOGY

Drug-in-adhesive patch overcomes many of the limitations of patches currently on the market:

- High payload
  - » Suitable for lower potency drugs
  - » Smaller patch
- Better adhesion
  - » Full dose delivered
  - » Moisture resistant
  - » No cold-flow
- Solvent-free manufacturing process



To find out more please contact the Medherant team

Phone: +44 (0)24 7632 3060 | Email: [info@medherant.co.uk](mailto:info@medherant.co.uk) | [www.medherant.co.uk](http://www.medherant.co.uk)